Elizabeth Brem, MD, on Which CLL Abstract From ASH 2022 Can’t Be Ignored

In the latest episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, Clinical Associate Professor in the School of Medicine at the University of California, Irvine, off the heels of the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Brem discusses which chronic lymphocytic leukemia (CLL) abstracts from ASH 2022 cannot be ignored, the latest news in Richter’s transformation, and why she is moving away from ibrutinib in her own clinical practice.